Interpreting Stock Reactions To Reverse-Payment Settlements
When branded drug companies settle patent litigation (known as Paragraph IV or Hatch-Waxman litigation) with would-be generic competitors, they sometimes enter into contemporaneous business agreements with the generic companies. There is...To view the full article, register now.
Already a subscriber? Click here to view full article